Table 1.
Clinicopathologic characteristics of patients according to age before and after propensity score matching
| Operation stage | Characteristics | Before propensity score matching | After propensity score matching | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Overall (n=2057) | Patients aged ≤50 years (n=169) | Patients aged >50 years (n=1888) | P | Overall (n=790) | Patients aged ≤50 years (n=158) | Patients aged >50 years (n=632) | P | ||
| Preoperation | Follow-up (month), mean±s.d. | 53.80±29.05 | 57.74±31.74 | 53.45±28.78 | 0.091# | 52.65±28.59 | 59.11±31.79 | 51.03±27.52 | 0.004# |
| BMI (kg m−2) | 34.80±24.30 | 24.34±2.49 | 24.30±2.59 | 0.848# | 24.35±2.56 | 24.27±2.51 | 24.37±2.57 | 0.645# | |
| HTN, n (%) | 878 (42.7) | 30 (17.8) | 848 (44.9) | <0.001* | 157 (19.9) | 30 (19.0) | 127 (20.1) | 0.755* | |
| DM, n (%) | 321 (15.6) | 18 (10.7) | 303 (16.0) | 0.064* | 95 (12.0) | 18 (11.4) | 77 (12.2) | 0.784* | |
| PSA (ng ml−1) | 12.15±14.32 | 9.59±8.61 | 12.38±14.70 | <0.001# | 9.85±9.77 | 9.82±8.84 | 9.86±9.99 | <0.001# | |
| PSA <10, n (%) | 1315 (63.9) | 119 (70.4) | 1196 (63.3) | 0.110* | 554 (70.1) | 109 (69.0) | 445 (70.4) | 0.871* | |
| 10 ≤PSA ≤20, n (%) | 464 (22.6) | 35 (20.7) | 429 (22.7) | 169 (21.4) | 34 (21.5) | 135 (21.4) | |||
| PSA >20, n (%) | 278 (13.5) | 15 (8.9) | 263 (13.9) | 67 (8.5) | 15 (9.5) | 52 (8.2) | |||
| Prostate volume (ml) | 40.37±16.85 | 34.15±9.04 | 40.92±12.27 | <0.001# | 31.27±9.92 | 34.48±9.18 | 31.22±10.10 | 0.773# | |
| Biopsy GS, n (%) | 0.017* | 0.855* | |||||||
| <7 | 957 (46.5) | 94 (55.6) | 863 (45.7) | 421 (53.3) | 87 (55.1) | 334 (52.8) | |||
| =7 | 778 (37.8) | 59 (34.9) | 719 (38.1) | 290 (36.7) | 55 (34.8) | 235 (37.2) | |||
| >7 | 322 (15.7) | 16 (9.5) | 306 (16.2) | 79 (10.0) | 16 (10.1) | 63 (10.0) | |||
| Clinical stage, n (%) | 0.020* | 0.888* | |||||||
| T1c | 1219 (59.3) | 115 (68.0) | 1104 (58.5) | 536 (67.8) | 107 (67.7) | 429 (67.9) | |||
| T2a-b | 605 (29.4) | 44 (26.0) | 561 (29.7) | 203 (25.7) | 42 (26.6) | 161 (25.5) | |||
| T2c | 233 (11.3) | 10 (5.9) | 223 (11.8) | 51 (6.5) | 9 (5.7) | 42 (6.6) | |||
| D’Amico risk stratification, n (%) | 0.001* | 0.756 | |||||||
| Low | 743 (36.1) | 79 (46.7) | 664 (35.2) | 345 (43.7) | 73 (46.2) | 272 (43.0) | |||
| Intermediate | 744 (36.2) | 62 (36.7) | 682 (36.1) | 308 (39.0) | 58 (36.7) | 250 (39.6) | |||
| High | 570 (27.7) | 28 (16.6) | 542 (28.7) | 137 (17.3) | 27 (17.1) | 110 (17.4) | |||
| Perioperation | Nerve sparing (+), n (%) | 1412 (68.6) | 159 (94.1) | 1253 (66.4) | <0.001* | 604 (76.5) | 149 (94.3) | 455 (72.0) | <0.001* |
| Unilateral | 186 (9.0) | 17 (10.1) | 618 (32.7) | 78 (9.9) | 16 (10.1) | 62 (9.8) | |||
| Bilateral | 1226 (59.6) | 142 (84.0) | 635 (33.6) | 526 (66.6) | 133 (84.2) | 393 (62.2) | |||
| Postoperation | Pathologic GS, n (%) | <0.001* | 0.002* | ||||||
| <7 | 245 (11.9) | 36 (21.3) | 209 (11.1) | 107 (13.5) | 34 (21.5) | 73 (11.6) | |||
| =7 | 1565 (76.1) | 117 (69.2) | 1448 (76.7) | 616 (78.0) | 108 (68.4) | 508 (80.4) | |||
| >7 | 247 (12.0) | 16 (9.5) | 231 (12.2) | 67 (8.5) | 16 (10.1) | 51 (8.1) | |||
| ECE, n (%) | 611 (29.7) | 27 (16.0) | 584 (30.9) | <0.001* | 189 (23.9) | 24 (15.2) | 165 (26.1) | 0.004* | |
| SVI, n (%) | 175 (8.5) | 6 (3.6) | 169 (9.0) | 0.016* | 42 (5.3) | 6 (3.8) | 36 (5.7) | 0.341* | |
| PSM, n (%) | 566 (27.5) | 37 (21.9) | 529 (28.0) | 0.088* | 196 (24.8) | 35 (22.2) | 161 (25.5) | 0.387* | |
| Confirmed LNI, n (%) | 38 (1.8) | 3 (1.8) | 35 (1.9) | 0.942* | 11 (1.4) | 3 (1.9) | 8 (1.3) | 0.544* | |
| BCR status (+), n (%) | 436 (21.2) | 35 (20.7) | 401 (21.2) | 0.872* | 127 (16.1) | 33 (20.9) | 94 (14.9) | 0.066* | |
| Follow-up time until BCR (month), mean±s.d. | 20.97±22.45 | 19.91±22.72 | 21.06±22.45 | 0.775# | 20.38±22.30 | 20.24±23.20 | 20.43±22.10 | 0.969* | |
*The P values were calculated using the t-test model, #the P values were calculated using the Chi-square model. BMI: body mass index; HTN: hypertension; DM: diabetes mellitus; PSA: prostate-specific antigen; GS: Gleason score; ECE: extracapsular extension; SVI: seminal vesicle invasion; PSM: positive surgical margin; LNI: lymphatic nodal invasion; BCR: biochemical recurrence; s.d.: standard deviation